The effect of sibutramine on non alcoholic fatty liver

The effect of low calorie diet with and without sibutramine on metabolic syndrome risk factors and sonographic findings in non alcoholic fatty liver

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201012275483N1

Enrollment

Registered

2011-01-28

Start date

2010-04-18

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non alcoholic fatty liver. Diseases of liver

Interventions

Intervention 1: Control group: vitamin E 400 IU supplement once daily and weight loss diet for 3 months. Intervention 2: Intervention group: 15-mg capsule of sibutramine once a day half an hour before

Treatment - Drugs

Control group: vitamin E 400 IU supplement once daily and weight loss diet for 3 months

Intervention group: 15-mg capsule of sibutramine once a day half an hour before lunch and vitamin E supplement (400 IU) once a day and weight loss diet for 3 months

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: non-alcoholic fatty liver disease, having 20 to 50 years old of both sexes, having BMI 30kg/m2 or more, willing to participate Exclusion criteria: Presence of thyroid disorders, diabetes, or uncontrolled hypertension, use of glucose, cholesterol, or triglyceride lowering drugs, estrogen or progesterone usage, supplementation of vitamin C, or E over the two months prior to the study, menopausal women, smoking and alcohol use, being athletes

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Liver echogenicity. Timepoint: before and after intervention. Method of measurement: sonography.;Weight. Timepoint: every two week. Method of measurement: Nestle scale.	—

Secondary

Measure	Time frame
Total cholestrol. Timepoint: at the beginning and end of the intervation. Method of measurement: enzymatic method with autoanalysis system.;LDL-C. Timepoint: at the beginning and end of the intervation. Method of measurement: enzymatic method with autoanalysis system.;HDL-C. Timepoint: at the beginning and end of the intervation. Method of measurement: enzymatic method with autoanalysis system.;Glucose. Timepoint: at the beginning and end of the intervation. Method of measurement: enzymatic method with autoanalysis system.;AST. Timepoint: at the beginning and end of the intervation. Method of measurement: ELISA.;ALT. Timepoint: at the beginning and end of the intervation. Method of measurement: spectrophotometery.;Ferritin. Timepoint: at the beginning and end of the intervation. Method of measurement: ELISA.;HbA1c. Timepoint: at the beginning and end of the intervation. Method of measurement: ELISA.;Trigliceride. Timepoint: at the beginning and end of the intervation. Method of measurement: enzymatic method with autoanalysis system.	—

Measure

Time frame

Total cholestrol. Timepoint: at the beginning and end of the intervation. Method of measurement: enzymatic method with autoanalysis system.;LDL-C. Timepoint: at the beginning and end of the intervation. Method of measurement: enzymatic method with autoanalysis system.;HDL-C. Timepoint: at the beginning and end of the intervation. Method of measurement: enzymatic method with autoanalysis system.;Glucose. Timepoint: at the beginning and end of the intervation. Method of measurement: enzymatic method with autoanalysis system.;AST. Timepoint: at the beginning and end of the intervation. Method of measurement: ELISA.;ALT. Timepoint: at the beginning and end of the intervation. Method of measurement: spectrophotometery.;Ferritin. Timepoint: at the beginning and end of the intervation. Method of measurement: ELISA.;HbA1c. Timepoint: at the beginning and end of the intervation. Method of measurement: ELISA.;Trigliceride. Timepoint: at the beginning and end of the intervation. Method of measurement: enzymatic method with autoanalysis system.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Bahmanabadi

School of health and nutrition, Aras International University

bahmanabadi2009@gmail.com bahmanabadi2009@yahoo.com+98 41 1335 7580

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026